Hypertrophic Cardiomyopathy, SAM & LVOT Obstruction

Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy is the most common inherited cardiac disease (autosomal dominant, sarcomeric protein gene mutations identified in roughly 60% of cases) and a leading cause of sudden cardiac death in young, otherwise healthy patients and athletes, making accurate echocardiographic recognition a genuine patient-safety priority.

Diagnostic criteria

• LV wall thickness ≥15 mm anywhere in the ventricle, unexplained by an abnormal loading condition (hypertension, aortic stenosis) or another disease process (e.g., infiltrative disease) that could otherwise produce a comparable degree of hypertrophy.
• ≥13 mm is diagnostic in a patient with a first-degree relative with confirmed HCM or a positive genetic test for a sarcomeric mutation.
• Asymmetric septal hypertrophy (ASH) is the most common morphologic pattern: the basal interventricular septum thickens disproportionately relative to the posterior/lateral wall, with a septal-to-posterior wall thickness ratio ≥1.3 commonly cited as supportive of the diagnosis. Apical, concentric, and mid-cavitary variants also occur and change the expected obstruction location.

Systolic Anterior Motion (SAM) and Dynamic LVOT Obstruction

In roughly two-thirds of HCM patients, the asymmetric septal bulge narrows the LV outflow tract and accelerates systolic flow through it. This high-velocity, narrowed-channel flow draws the anterior mitral leaflet — and often the associated chordae and papillary apparatus — toward the septum during systole, a phenomenon known as systolic anterior motion (SAM). Classic teaching attributes SAM to the Venturi effect, in which a zone of low pressure generated by high-velocity LVOT flow pulls the leaflet forward; more recent flow-mapping research indicates that drag forces from flow directly impacting the leaflet surface are the dominant hydraulic mechanism, with Venturi forces playing a smaller supporting role. Predisposing anatomic features include an elongated anterior mitral leaflet, anteriorly displaced papillary muscles, and a narrowed LVOT from the septal bulge.

SAM produces two simultaneous downstream consequences:

1. Dynamic (not fixed) LVOT obstruction — the degree of obstruction changes with loading conditions, contractility, and heart rate, unlike the fixed anatomic obstruction of valvular aortic stenosis.
2. Mitral regurgitation — septal-leaflet contact during SAM prevents normal leaflet coaptation, typically producing a posteriorly directed MR jet, because the anterior leaflet is pulled toward the septum and the resulting coaptation defect points posteriorly.

The dagger-shaped CW Doppler signature

Continuous-wave Doppler aligned through the LVOT jet, best obtained from the apical five-chamber or apical long-axis view, is essential for both detecting and quantifying obstruction. As the septum and anterior mitral leaflet progressively appose through systole, the degree of obstruction — and therefore the instantaneous velocity — increases as systole proceeds. This produces a characteristic dagger-shaped ('scimitar'), late-peaking high-velocity envelope, with peak velocity occurring in mid-to-late systole. This waveform shape is a key discriminator from fixed valvular aortic stenosis, whose CW envelope is more rounded and peaks earlier in systole, because a fixed orifice does not change size across the cardiac cycle. Because the SAM-related MR jet and the LVOT jet can be adjacent and co-directional in the apical window, careful 2D and color-guided alignment is needed so the higher-velocity MR jet does not contaminate the LVOT gradient measurement.

Quantifying the Gradient and Clinical Thresholds

Peak LVOT velocity is converted to a pressure gradient using the modified Bernoulli equation (ΔP = 4V²). This gradient is central to HCM risk stratification and management decisions and has been verified against current ASE/AHA-ACC guideline values.

Because obstruction is dynamic, a resting gradient below the significant threshold does not exclude clinically important obstruction. Provocative maneuvers are used to unmask latent obstruction whenever the resting study does not reach the relevant threshold in a symptomatic patient:

• Valsalva maneuver — the strain phase reduces preload and LV volume, narrowing the LVOT further and increasing the gradient.
• Exercise echocardiography (treadmill or supine bicycle) — the preferred physiologic provocation, since it best reproduces symptom-producing conditions; recommended when the resting or provoked TTE gradient is <50 mmHg in a symptomatic patient.
• Amyl nitrite — reduces systemic afterload and increases contractility; historically used in the catheterization laboratory, less common in the modern echo lab.
• Passive leg raise or standing — alters preload in a direction similar to Valsalva, though generally less potent.

Accurate gradient measurement and correct maneuver selection directly affect whether a patient is referred for invasive septal reduction therapy, making this one of the highest patient-safety-impact measurements on the AE exam.

M-mode and 2D grading of SAM severity

M-mode through the mitral valve, taken from the parasternal long-axis view, can grade SAM by the degree and duration of anterior leaflet excursion toward the septum during systole: mild SAM shows anterior motion without septal contact, while severe SAM shows prolonged mitral-septal contact that persists through a large portion of systole — the duration of contact correlates with the severity of the resulting LVOT gradient and with MR severity. Basal septal wall thickness should be measured in the parasternal long-axis view at end-diastole using the leading-edge-to-leading-edge technique, matched against the posterior wall at the same level, to calculate the septal-to-posterior wall thickness ratio used to support the ASH diagnosis. Because SAM-related MR is a downstream consequence of outflow obstruction rather than primary leaflet disease, its severity typically improves in parallel with successful reduction of the LVOT gradient (medically or with septal reduction therapy), which is an important distinction from primary degenerative MR when counseling patients on expected outcomes.